Multinational pharmaceutical companies in the near future big action! Channel sinking and "throwing off the burden"

[pharmaceutical industry news] China economic network reported that Beijing Economic and Technological Development Zone and AstraZeneca signed a memorandum of strategic cooperation recently AstraZeneca's headquarters in northern China will be located in the economic development zone, covering relevant regional operation management, sales market, logistics and distribution, new drug research and development and other businesses At the same time, the two sides will jointly establish a Sino British Cooperation Demonstration Park and introduce medical and health resources and advanced technologies from the UK and the world According to the data, the output value of biomedical and health industries in the economic development zone has accounted for more than 50% in Beijing for five consecutive years In 2018, the output value reached 46.66 billion yuan In the first half of this year, the output value reached 29.12 billion yuan, an increase of 16.2% year on year AstraZeneca's presence in Yizhuang marks a new addition to the biomedical industry in the economic development zone According to the analysis of insiders, the Chinese market is one of the core growth points of innovative medicine business of multinational pharmaceutical enterprises in recent years With the integration of innovative medicine into medical insurance, it will help overseas pharmaceutical enterprises to further expand the Chinese market In addition to AstraZeneca, on May 30, 2019, "puqiang global headquarters" was unveiled in Shanghai, which is Pfizer's global management center of business sector located overseas in the United States; on March 6, Novo Nordisk China R & D center announced the launch of Innovo platform, accelerating the development of innovative drugs through cooperation with local scientific research institutions and start-ups In terms of channel sinking of multinational pharmaceutical enterprises, Merck has a new way to play the channel sinking after Sanofi set up a basic medical business unit and Pfizer reduced the price of products Merck recently moved its life science business to Alibaba B2B platform 1688 It is reported that in the future, the products launched in the flagship store of life science will not be limited to the field of life science, but also include other products of Merck group Merck will continue to integrate into China to meet customer requirements and improve customer experience In 2019, the "4 + 7" volume procurement policy continued to advance, gradually pushed to the whole country from the original "4 + 7" pilot city, which not only affected local pharmaceutical enterprises, but also had a significant impact on multinational pharmaceutical enterprises The industry believes that volume purchasing will have an impact on the original research drugs of multinational pharmaceutical companies In order to prevent some products from affecting the performance, multinational pharmaceutical companies generally consider making the decision of "throwing off the burden" and focusing on the core business Recently, the company under Novartis Group signed a transfer agreement with Jiuzhou Pharmaceutical Co., Ltd to transfer 100% equity of Suzhou Novartis after divestiture of technology and drug development assets According to the announcement issued by Jiuzhou pharmaceutical industry, Novartis international pharmaceutical investment Co., Ltd plans to sell 100% equity of Suzhou Novartis after divestiture of technology and drug development assets for 790 million yuan Novartis said the company's decision to sell the assets was based on business needs and the needs of patients and customers In July, Fosun Pharmaceutical announced that GSK had signed an agreement with the company to sell 100% equity of GlaxoSmithKline (Suzhou) Co., Ltd to Fosun Pharmaceutical, including the drug registration approval of lamivudine (specification: 0.1g) for chronic hepatitis B treatment, the production license and GMP certificate of its production facilities In April, Yiteng pharmaceutical announced that Lilly pharmaceutical would sell to Yiteng pharmaceutical the rights of its antibiotic product, secolo, and its reliable production plant in Suzhou In general, with the development environment of new drugs in China becoming better, more and more multinational pharmaceutical companies will be attracted to increase the scale, bringing good news for domestic patients In the future, it will become a trend for multinational pharmaceutical companies to cooperate with local start-ups to develop new drugs In the process of competition with local pharmaceutical companies, multinational pharmaceutical companies have to make a series of strategic adjustments in order to occupy more Chinese market In the future, the competition between local pharmaceutical enterprises and transnational pharmaceutical enterprises will be more intense and the cooperation will be closer.